Literature DB >> 14657286

Measurement of 18F-FDG concentrations in blood samples: comparison of direct calibration and standard solution methods.

Henri N J M Greuter1, Ronald Boellaard, Arthur van Lingen, Eric J F Franssen, Adriaan A Lammertsma.   

Abstract

OBJECTIVE: The purpose of this study was to compare the accuracy and reliability of 2 well counter methods for measuring the activity concentration of (18)F-FDG in blood samples.
METHODS: Three to 5 blood samples from 154 patient studies were weighed and measured in a well counter. The (18)F-FDG activity concentration was derived using, first, a direct calibration factor to convert measured well counter readings into activity concentration and, second, a comparison of measured counts with those of a specified standard solution.
RESULTS: The ratio between the activity concentration results of the 2 methods was 0.996 +/- 0.033, indicating that the methods provided equal results.
CONCLUSION: Because the standard solution method is more prone to human error, less reproducible, and more labor intensive, preference should be given to the direct calibration method.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14657286

Source DB:  PubMed          Journal:  J Nucl Med Technol        ISSN: 0091-4916


  6 in total

1.  The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials.

Authors:  Ronald Boellaard; Wim J G Oyen; Corneline J Hoekstra; Otto S Hoekstra; Eric P Visser; Antoon T Willemsen; Bertjan Arends; Fred J Verzijlbergen; Josee Zijlstra; Anne M Paans; Emile F I Comans; Jan Pruim
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08-15       Impact factor: 9.236

2.  Quantification of FDG PET studies using standardised uptake values in multi-centre trials: effects of image reconstruction, resolution and ROI definition parameters.

Authors:  Marinke Westerterp; Jan Pruim; Wim Oyen; Otto Hoekstra; Anne Paans; Eric Visser; Jan van Lanschot; Gerrit Sloof; Ronald Boellaard
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-10-11       Impact factor: 9.236

Review 3.  Methodological considerations in quantification of oncological FDG PET studies.

Authors:  Dennis Vriens; Eric P Visser; Lioe-Fee de Geus-Oei; Wim J G Oyen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-11-20       Impact factor: 9.236

4.  FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0.

Authors:  Ronald Boellaard; Mike J O'Doherty; Wolfgang A Weber; Felix M Mottaghy; Markus N Lonsdale; Sigrid G Stroobants; Wim J G Oyen; Joerg Kotzerke; Otto S Hoekstra; Jan Pruim; Paul K Marsden; Klaus Tatsch; Corneline J Hoekstra; Eric P Visser; Bertjan Arends; Fred J Verzijlbergen; Josee M Zijlstra; Emile F I Comans; Adriaan A Lammertsma; Anne M Paans; Antoon T Willemsen; Thomas Beyer; Andreas Bockisch; Cornelia Schaefer-Prokop; Dominique Delbeke; Richard P Baum; Arturo Chiti; Bernd J Krause
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

Review 5.  Simultaneous PET-MRI in oncology: a solution looking for a problem?

Authors:  Thomas E Yankeelov; Todd E Peterson; Richard G Abramson; David Izquierdo-Garcia; David Garcia-Izquierdo; Lori R Arlinghaus; Xia Li; Nkiruka C Atuegwu; Ciprian Catana; H Charles Manning; Zahi A Fayad; John C Gore
Journal:  Magn Reson Imaging       Date:  2012-07-15       Impact factor: 2.546

6.  FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0.

Authors:  Ronald Boellaard; Roberto Delgado-Bolton; Wim J G Oyen; Francesco Giammarile; Klaus Tatsch; Wolfgang Eschner; Fred J Verzijlbergen; Sally F Barrington; Lucy C Pike; Wolfgang A Weber; Sigrid Stroobants; Dominique Delbeke; Kevin J Donohoe; Scott Holbrook; Michael M Graham; Giorgio Testanera; Otto S Hoekstra; Josee Zijlstra; Eric Visser; Corneline J Hoekstra; Jan Pruim; Antoon Willemsen; Bertjan Arends; Jörg Kotzerke; Andreas Bockisch; Thomas Beyer; Arturo Chiti; Bernd J Krause
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-12-02       Impact factor: 9.236

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.